

# Matthias Barton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6319597/publications.pdf>

Version: 2024-02-01

147  
papers

9,590  
citations

41627

51  
h-index

45040

94  
g-index

153  
all docs

153  
docs citations

153  
times ranked

10051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. <i>Cardiovascular Research</i> , 2022, 118, 988-1003.	1.8	12
2	Exercise is medicine: key to cardiovascular disease and diabetes prevention. <i>Cardiovascular Research</i> , 2021, 117, 360-363.	1.8	4
3	Role of Perivascular Adipose Tissue for Sex Differences in Coronary Artery Disease and Spontaneous Coronary Artery Dissection (SCAD). <i>Endocrine and Metabolic Science</i> , 2021, 2, 100068.	0.7	4
4	Steroid Hormones and Receptors in Health and Disease. <i>FASEB Journal</i> , 2021, 35, e21858.	0.2	1
5	Serum from Patients with Severe Alcoholic Liver Cirrhosis Inhibits Proliferation and Migration of Human Coronary Artery Smooth Muscle Cells. <i>Journal of Clinical Medicine</i> , 2021, 10, 5471.	1.0	2
6	Linking regulation of nitric oxide to endothelin-1: The Yin and Yang of vascular tone in the atherosclerotic plaque. <i>Atherosclerosis</i> , 2020, 292, 201-203.	0.4	13
7	Early life stress determines insulin signalling in adulthood. <i>Journal of Physiology</i> , 2020, 598, 427-428.	1.3	3
8	Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. <i>ELife</i> , 2020, 9, .	2.8	121
9	Heart Failure With Preserved Ejection Fraction in Women. <i>JACC Basic To Translational Science</i> , 2020, 5, 296-299.	1.9	12
10	Tomoh Masaki. <i>Hypertension</i> , 2020, 76, 1664-1666.	1.3	1
11	Endothelin: 30 Years From Discovery to Therapy. <i>Hypertension</i> , 2019, 74, 1232-1265.	1.3	153
12	Nox1 downregulators: A new class of therapeutics. <i>Steroids</i> , 2019, 152, 108494.	0.8	16
13	Primum Non Nocere. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 117-120.	1.1	5
14	HuR-ry Up. <i>Circulation</i> , 2019, 139, 115-118.	1.6	19
15	Permissive Role of GPER for Arterial Hypertension. <i>Hypertension</i> , 2019, 73, e9-e10.	1.3	3
16	Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 176, 4-15.	1.2	183
17	GPER blockers as Nox downregulators: A new drug class to target chronic non-communicable diseases. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 176, 82-87.	1.2	14
18	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. <i>Journal of Hypertension</i> , 2018, 36, 451-461.	0.3	19

#	ARTICLE	IF	CITATIONS
19	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. Journal of Hypertension, 2018, 36, 462-471.	0.3	13
20	Rapid vasodilation to raloxifene: role of oestrogen receptors and off-target effects. British Journal of Pharmacology, 2017, 174, 4201-4202.	2.7	2
21	GPER Mediates Functional Endothelial Aging in Renal Arteries. Pharmacology, 2017, 100, 188-193.	0.9	15
22	Obesity causes lymphatic vascular injury: time for clinical translation. Journal of Physiology, 2016, 594, 6807-6808.	1.3	3
23	Estrogen Signaling in the Adrenal Cortex. Hypertension, 2016, 68, 840-848.	1.3	27
24	Obligatory role for GPER in cardiovascular aging and disease. Science Signaling, 2016, 9, ra105.	1.6	54
25	GPER is required for the age-dependent upregulation of the myocardial endothelin system. Life Sciences, 2016, 159, 61-65.	2.0	12
26	Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. Canadian Journal of Cardiology, 2016, 32, 680-686.e4.	0.8	41
27	Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER. Steroids, 2016, 111, 37-45.	0.8	47
28	Endothelin and the Glomerulus in Chronic Kidney Disease. Seminars in Nephrology, 2015, 35, 156-167.	0.6	37
29	Emerging roles of GPER in diabetes and atherosclerosis. Trends in Endocrinology and Metabolism, 2015, 26, 185-192.	3.1	83
30	G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity. Journal of Endocrinology, 2015, 227, 61-69.	1.2	32
31	Nicolaus Copernicus and the rapid vascular responses to aldosterone. Trends in Endocrinology and Metabolism, 2015, 26, 396-398.	3.1	24
32	Advancing and Translating Knowledge in Vascular Medicine. Frontiers in Cardiovascular Medicine, 2014, 1, 6.	1.1	3
33	Balloon Angioplasty – The Legacy of Andreas Gruntzig, M.D. (1939–1985). Frontiers in Cardiovascular Medicine, 2014, 1, 15.	1.1	66
34	25Years of endothelin research: the next generation. Life Sciences, 2014, 118, 77-86.	2.0	8
35	Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents. Life Sciences, 2014, 118, 206-212.	2.0	12
36	Estrogen biology: New insights into GPER function and clinical opportunities. Molecular and Cellular Endocrinology, 2014, 389, 71-83.	1.6	314

#	ARTICLE	IF	CITATIONS
37	Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries. <i>Life Sciences</i> , 2014, 118, 213-218.	2.0	16
38	Aging and endothelin: Determinants of disease. <i>Life Sciences</i> , 2014, 118, 97-109.	2.0	47
39	Endothelin and endothelin antagonists in chronic kidney disease. <i>Kidney International</i> , 2014, 86, 896-904.	2.6	201
40	Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging. <i>Life Sciences</i> , 2014, 118, 226-231.	2.0	13
41	G Protein-coupled Estrogen Receptor Protects from Atherosclerosis. <i>Scientific Reports</i> , 2014, 4, 7564.	1.6	122
42	Mechanisms and therapy of atherosclerosis and its clinical complications. <i>Current Opinion in Pharmacology</i> , 2013, 13, 149-153.	1.7	16
43	Themed section: endothelin. <i>British Journal of Pharmacology</i> , 2013, 168, 279-282.	2.7	1
44	Prevention and endothelial therapy of coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 226-241.	1.7	61
45	Cholesterol and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2013, 24, 214-220.	1.2	96
46	Endothelin in Coronary Artery Disease and Myocardial Infarction. <i>Cardiology in Review</i> , 2013, 21, 249-256.	0.6	68
47	Alike but Not the Same. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 22-25.	0.8	11
48	Regulation of Vascular Smooth Muscle Tone by Adipose-Derived Contracting Factor. <i>PLoS ONE</i> , 2013, 8, e79245.	1.1	65
49	Testosterone and Secondary Hypertension. <i>Hypertension</i> , 2012, 59, 1101-1103.	1.3	16
50	Deletion of G Proteinâ€‘Coupled Estrogen Receptor Increases Endothelial Vasoconstriction. <i>Hypertension</i> , 2012, 59, 507-512.	1.3	55
51	Endothelin and the podocyte. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 17-27.	1.4	37
52	Childhood obesity: a life-long health risk. <i>Acta Pharmacologica Sinica</i> , 2012, 33, 189-193.	2.8	89
53	Position paper: The membrane estrogen receptor GPER â€‘ Clues and questions. <i>Steroids</i> , 2012, 77, 935-942.	0.8	105
54	GPER regulates endothelin-dependent vascular tone and intracellular calcium. <i>Life Sciences</i> , 2012, 91, 623-627.	2.0	63

#	ARTICLE	IF	CITATIONS
55	The future of endothelin research: Scientific mentoring and beyond. <i>Life Sciences</i> , 2012, 91, 470-474.	2.0	12
56	Endothelin XII. <i>Life Sciences</i> , 2012, 91, 449-451.	2.0	7
57	The First Tomoh Masaki Award (2011). <i>Life Sciences</i> , 2012, 91, 466-469.	2.0	9
58	Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. <i>Life Sciences</i> , 2012, 91, 528-539.	2.0	76
59	Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. <i>British Journal of Pharmacology</i> , 2012, 165, 591-602.	2.7	95
60	Endothelin Receptor Antagonists in Cardiovascular Medicine: Challenges and Opportunities. , 2012, , 231-259.		0
61	Acute inhibition but not chronic deficiency of G protein-coupled estrogen receptor reduces bioactivity of nitric oxide. <i>FASEB Journal</i> , 2012, 26, 1131.10.	0.2	0
62	The discovery of endothelium-dependent contraction: The legacy of Paul M. Vanhoutte. <i>Pharmacological Research</i> , 2011, 63, 455-462.	3.1	33
63	The G-protein-coupled estrogen receptor GPER in health and disease. <i>Nature Reviews Endocrinology</i> , 2011, 7, 715-726.	4.3	710
64	Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. <i>Acta Physiologica</i> , 2011, 203, 259-269.	1.8	242
65	The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. <i>Vascular Pharmacology</i> , 2011, 55, 17-25.	1.0	135
66	Estrogen-Independent Activation of Estrogen Receptors. <i>Hypertension</i> , 2011, 57, 1056-1057.	1.3	11
67	Endothelin Antagonists in Clinical Trials: Lessons Learned. <i>Contributions To Nephrology</i> , 2011, 172, 255-260.	1.1	20
68	Endothelin Antagonism and Reversal of Proteinuric Renal Disease in Humans. <i>Contributions To Nephrology</i> , 2011, 172, 210-222.	1.1	8
69	GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 255-261.	0.5	25
70	Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. <i>Pflugers Archiv European Journal of Physiology</i> , 2010, 460, 825-837.	1.3	88
71	Dilation of Epicardial Coronary Arteries by the G Protein-Coupled Estrogen Receptor Agonists G-1 and ICI 182,780. <i>Pharmacology</i> , 2010, 86, 58-64.	0.9	106
72	Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 1203-1213.	1.8	46

#	ARTICLE	IF	CITATIONS
73	Lung cancer and hormone replacement therapy. <i>Lancet, The</i> , 2010, 375, 117-118.	6.3	0
74	Postmenopausal Hypertension. <i>Hypertension</i> , 2009, 54, 11-18.	1.3	164
75	Getting Radical About Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 447-448.	1.1	1
76	Regulatory Role of G Proteinâ€‘Coupled Estrogen Receptor for Vascular Function and Obesity. <i>Circulation Research</i> , 2009, 104, 288-291.	2.0	311
77	ER $\alpha$ , ER $\beta$ , and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. <i>Cardiovascular Research</i> , 2009, 83, 605-610.	1.8	48
78	Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. <i>Prostaglandins and Other Lipid Mediators</i> , 2009, 89, 89-97.	1.0	146
79	Non-genomic regulation of vascular cell function and growth by estrogen. <i>Molecular and Cellular Endocrinology</i> , 2009, 308, 9-16.	1.6	103
80	Fat intake and cardiovascular response. <i>Current Hypertension Reports</i> , 2008, 10, 25-31.	1.5	34
81	Regional Heterogeneity of Functional Changes in Conduit Arteries After High-fat Diet. <i>Obesity</i> , 2008, 16, 743-748.	1.5	25
82	Need for research on estrogen receptor function: Importance for postmenopausal hormone therapy and atherosclerosis. <i>Gender Medicine</i> , 2008, 5, S19-S33.	1.4	29
83	Endothelin: 20 years from discovery to therapy This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 485-498.	0.7	275
84	Reversal of proteinuric renal disease and the emerging role of endothelin. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 490-501.	2.0	93
85	Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 563-567.	1.9	12
86	Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1669-1672.	1.1	45
87	Endothelin stimulates vascular hydroxyl radical formation: effect of obesity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R2218-R2224.	0.9	16
88	Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity. <i>Cardiovascular Research</i> , 2007, 73, 368-375.	1.8	60
89	Differential Effects of 17 $\beta$ -Estradiol on Function and Expression of Estrogen Receptor $\alpha$ , Estrogen Receptor $\beta$ , and GPR30 in Arteries and Veins of Patients With Atherosclerosis. <i>Hypertension</i> , 2007, 49, 1358-1363.	1.3	153
90	Distinct Roles of Estrogen Receptors $\alpha$ and $\beta$ Mediating Acute Vasodilation of Epicardial Coronary Arteries. <i>Hypertension</i> , 2007, 49, 1364-1370.	1.3	87

#	ARTICLE	IF	CITATIONS
91	Inflammation and Atherosclerosis. <i>Circulation Research</i> , 2007, 101, 750-751.	2.0	21
92	Impaired vascular function in normoglycemic mice prone to autoimmune diabetes: Role of nitric oxide. <i>European Journal of Pharmacology</i> , 2007, 557, 161-167.	1.7	2
93	Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus. <i>Life Sciences</i> , 2006, 78, 2213-2218.	2.0	24
94	Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 265-276.	1.5	15
95	Early Aging and Anatomic Heterogeneity Determine Cyclooxygenase-mediated Vasoconstriction to Angiotensin II in Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 48, 30-33.	0.8	14
96	Role of Endothelin Receptors for Renal Protection and Survival in Hypertension. <i>Hypertension</i> , 2006, 48, 834-837.	1.3	18
97	Gender Differences of Cardiovascular Disease. <i>Hypertension</i> , 2006, 47, 1019-1026.	1.3	137
98	Postural Effects on Interstitial Fluid Pressure in Humans. <i>Journal of Vascular Research</i> , 2006, 43, 321-326.	0.6	19
99	Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries. <i>Experimental Biology and Medicine</i> , 2006, 231, 777-81.	1.1	8
100	Ageing as a determinant of renal and vascular disease: role of endothelial factors. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 485-490.	0.4	34
101	Activation of Pro-Inflammatory and Anti-Inflammatory Cytokines in Host Organs During Chronic Allograft Rejection: Role of Endothelin Receptor Signaling. <i>American Journal of Transplantation</i> , 2005, 5, 1042-1049.	2.6	47
102	Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. <i>Cardiovascular Research</i> , 2005, 66, 295-306.	1.8	197
103	Aging and biomedicine 2005: Where should we go from here?. <i>Cardiovascular Research</i> , 2005, 66, 187-189.	1.8	13
104	Anatomically distinct activation of endothelin-3 and the l-arginine/nitric oxide pathway in the kidney with advanced aging. <i>Biochemical and Biophysical Research Communications</i> , 2005, 327, 234-241.	1.0	20
105	Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: Evidence for endothelin release by pancreatic islet $\beta$ -cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 689-695.	1.0	24
106	Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 747-753.	1.0	26
107	Role of Podocytes for Reversal of Glomerulosclerosis and Proteinuria in the Aging Kidney After Endothelin Inhibition. <i>Hypertension</i> , 2004, 44, 974-981.	1.3	135
108	Protective role of ETA endothelin receptors during the acute phase of <i>Trypanosoma cruzi</i> infection in rats. <i>Microbes and Infection</i> , 2004, 6, 650-656.	1.0	20

#	ARTICLE	IF	CITATIONS
109	Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. <i>Biochemical and Biophysical Research Communications</i> , 2003, 302, 67-72.	1.0	48
110	Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 826-837.	1.2	98
111	Cardiovascular consequences of the obesity pandemic: need for action. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1757-1759.	1.9	31
112	Endothelial Therapy of Atherosclerosis and its Risk Factors. <i>Current Vascular Pharmacology</i> , 2003, 1, 111-121.	0.8	26
113	Endothelin, hypercholesterolemia and atherosclerosis. <i>Coronary Artery Disease</i> , 2003, 14, 477-490.	0.3	33
114	Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. <i>Cardiovascular Research</i> , 2002, 53, 487-495.	1.8	41
115	Oral contraceptives and the risk of thrombosis and atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 329-332.	1.9	9
116	Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. <i>Journal of Hypertension</i> , 2002, 20, 2239-2245.	0.3	124
117	Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. <i>Clinical Science</i> , 2002, 103, 13S-15S.	1.8	34
118	Acute effects of 17 $\beta$ -oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins. <i>Clinical Science</i> , 2002, 103, 438S-441S.	1.8	6
119	Estrogen and apoptosis in atherosclerosis. <i>International Congress Series</i> , 2002, 1229, 81-93.	0.2	1
120	Native LDL Induces Proliferation of Human Vascular Smooth Muscle Cells via Redox-Mediated Activation of ERK 1/2 Mitogen-Activated Protein Kinases. <i>Hypertension</i> , 2002, 39, 645-650.	1.3	62
121	Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. <i>European Journal of Pharmacology</i> , 2002, 434, 1-7.	1.7	44
122	Increased Expression of Endothelin-1 and Inducible Nitric Oxide Synthase Isoform II in Aging Arteries in Vivo: Implications for Atherosclerosis. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 908-913.	1.0	98
123	Endothelium and Atherogenesis: Endothelial Therapy Revisited. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S23-S25.	0.8	45
124	The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. <i>Current Hypertension Reports</i> , 2001, 3, 322-330.	1.5	26
125	Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 789-809.	1.9	12
126	Endothelial dysfunction and atherosclerosis: Endothelin receptor antagonists as novel therapeutics. <i>Current Hypertension Reports</i> , 2000, 2, 84-91.	1.5	46



#	ARTICLE	IF	CITATIONS
127	Assessment of Coronary Flow Reserve by Contrast-Enhanced Second Harmonic Echo Doppler. <i>Circulation</i> , 2000, 101, E100.	1.6	2
128	Endothelin Regulates Angiotensin-Converting Enzyme in the Mouse Kidney. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S244-S247.	0.8	12
129	Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo. <i>Hypertension</i> , 2000, 35, 329-336.	1.3	117
130	Endothelins and Endothelin Receptor Antagonists. <i>Circulation</i> , 2000, 102, 2434-2440.	1.6	536
131	Endothelin in Atherosclerosis: Importance of Risk Factors and Therapeutic Implications. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S55-S59.	0.8	30
132	Dysfunctional Renal Nitric Oxide Synthase as a Determinant of Salt-Sensitive Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 835-845.	3.0	91
133	Endothelin in heart failure. <i>Current Hypertension Reports</i> , 1999, 1, 62-68.	1.5	7
134	Endothelin antagonists for hypertension and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 549-556.	1.0	30
135	Estrogen and vascular resistance. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 218.	0.6	3
136	Endothelial Dysfunction in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 953-962.	3.0	42
137	17 $\beta$ -Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. <i>European Journal of Pharmacology</i> , 1998, 362, 73-76.	1.7	31
138	ET <sub>A</sub> Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive Hypertension. <i>Hypertension</i> , 1998, 31, 499-504.	1.3	167
139	Losartan but Not Verapamil Inhibits Angiotensin II-Induced Tissue Endothelin-1 Increase. <i>Hypertension</i> , 1998, 31, 1305-1310.	1.3	97
140	Endothelium-Independent Relaxation and Hyperpolarization to C-Type Natriuretic Peptide in Porcine Coronary Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 377-383.	0.8	49
141	Contractile Responses to Histamine, Serotonin, and Angiotensin II Are Impaired by 17 $\beta$ -Estradiol in Human Internal Mammary Arteries in vitro. <i>Pharmacology</i> , 1997, 54, 162-168.	0.9	28
142	Effects of Chronic ET A -Receptor Blockade in Angiotensin II-Induced Hypertension. <i>Hypertension</i> , 1997, 29, 435-441.	1.3	141
143	Angiotensin II Increases Vascular and Renal Endothelin-1 and Functional Endothelin Converting Enzyme Activity in Vivo: Role of ET A Receptors for Endothelin Regulation. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 861-865.	1.0	191
144	Biology of the Endothelium. <i>Clinical Cardiology</i> , 1997, 20, II-3.	0.7	243

#	ARTICLE	IF	CITATIONS
145	Angiotensin II Increases Tissue Endothelin and Induces Vascular Hypertrophy. <i>Circulation</i> , 1997, 96, 1593-1597.	1.6	249
146	Anatomic Heterogeneity of Vascular Aging. <i>Hypertension</i> , 1997, 30, 817-824.	1.3	178
147	Structure and Function of Small Arteries in Salt-Induced Hypertension. <i>Hypertension</i> , 1997, 30, 905-911.	1.3	91